GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
GALECTIN THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.13 (-3.45%)
Close on Oct 19, 2026
- Market cap
- $230.23M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Galectin Therapeutics has not reported a dividend
No dividend per share appears in Galectin Therapeutics's annual filings since fiscal 2010.